Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications
International Journal of Molecular Sciences · 15.08.2026 · 27 (16) · 7286
DOI: 10.3390/ijms27167286 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.08.2026. Verfasst von Georgios Mandrakis und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 10679 Athens, Greece. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Drug Resistance, Neoplasm, RNA, Untranslated, Gastrointestinal Neoplasms. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and are usually driven by activating mutations in KIT or PDGFRA. Although these alterations define the core molecular biology of GISTs and guide targeted therapy, they do not fully explain the variability observed in tumor behavior, recurrence risk, or response to tyrosine kinase inhibitors. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been increasingly studied as regulators of gene expression in GISTs. Recent evidence suggests that these molecules may influence KIT-centered signaling, autophagy, apoptosis, invasion, angiogenesis, and drug resistance. However, the strength of evidence differs considerably across individual ncRNAs, ranging from bioinformatic associations to functional validation in cell lines and in vivo models. This review summarizes current knowledge on ncRNA-mediated regulation in GIST biology, with emphasis on tumor progression, therapeutic resistance, and possible clinical relevance. Rather than treating ncRNAs as isolated biomarkers, they function as part of broader regulatory networks that interact with oncogenic signaling and epigenetic mechanisms. Although several ncRNAs appear promising as prognostic or predictive candidates, further validation in independent clinical cohorts is required before their integration into routine risk stratification or treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 10679 Athens, Greece.
- Department of Pathology, Paracelsus Medical University, 90419 Nuremberg, Germany.
- Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus.
ORCID-Profile: Georgios Mandrakis, Stavros P Papadakos, Georgia Levidou, Panoraia Keratsa, Maria-Ioanna Christodoulou
Zitieren
APA
Mandrakis, G., Papadakos, S. P., Levidou, G., Keratsa, P., Christodoulou, M. I., & Theocharis, S. (2026). Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications. International Journal of Molecular Sciences, 27(16), 7286. https://doi.org/10.3390/ijms27167286
Vancouver
Mandrakis G, Papadakos SP, Levidou G, Keratsa P, Christodoulou MI, Theocharis S. Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications. International Journal of Molecular Sciences. 2026;27(16):7286. doi:10.3390/ijms27167286
BibTeX
@article{Mandrakis2026,
author = {Mandrakis, Georgios and Papadakos, Stavros P and Levidou, Georgia and Keratsa, Panoraia and Christodoulou, Maria-Ioanna and Theocharis, Stamatios},
title = {Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7286},
doi = {10.3390/ijms27167286}
}
EUVIMED